Catalysts / KYMR
Upcoming FDA decisions and readouts we track for Kymera Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Kymera Therapeutics (KYMR, listed on Nasdaq). It concerns KT-621 (Atopic dermatitis (oral STAT6 degrader)).
First on the list: the Phase 2B readout for KT-621 (Atopic dermatitis (oral STAT6 degrader)), guided by the company to Late 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR · Nasdaq | KT-621 | Atopic dermatitis (oral STAT6 degrader) | Late 2026 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList